Utilization of RNA polymerase I promoter and terminator sequences to develop a DNA transfection system for the study of hepatitis C virus internal ribosomal entry site-dependent translation

2007 ◽  
Vol 40 (1) ◽  
pp. 55-59 ◽  
Author(s):  
Jae-Ku Oem ◽  
Zhonghua Xiang ◽  
Yan Zhou ◽  
Lorne A. Babiuk ◽  
Qiang Liu
2021 ◽  
Vol 136 ◽  
pp. 111239
Author(s):  
Muhammad Usman Ashraf ◽  
Hafiz Muhammad Salman ◽  
Muhammad Farhan Khalid ◽  
Muhammad Haider Farooq Khan ◽  
Saima Anwar ◽  
...  

2004 ◽  
Vol 3 (5) ◽  
pp. 949-957 ◽  
Author(s):  
Henry Lu ◽  
Weiqun Li ◽  
William Stafford Noble ◽  
Donald Payan ◽  
D. C. Anderson

2010 ◽  
Vol 84 (11) ◽  
pp. 5824-5835 ◽  
Author(s):  
Takahiro Masaki ◽  
Ryosuke Suzuki ◽  
Mohsan Saeed ◽  
Ken-ichi Mori ◽  
Mami Matsuda ◽  
...  

ABSTRACT In this study, we used an RNA polymerase I (Pol I) transcription system for development of a reverse genetics protocol to produce hepatitis C virus (HCV), which is an uncapped positive-strand RNA virus. Transfection with a plasmid harboring HCV JFH-1 full-length cDNA flanked by a Pol I promoter and Pol I terminator yielded an unspliced RNA with no additional sequences at either end, resulting in efficient RNA replication within the cytoplasm and subsequent production of infectious virions. Using this technology, we developed a simple replicon trans-packaging system, in which transient transfection of two plasmids enables examination of viral genome replication and virion assembly as two separate steps. In addition, we established a stable cell line that constitutively produces HCV with a low mutation frequency of the viral genome. The effects of inhibitors of N-linked glycosylation on HCV production were evaluated using this cell line, and the results suggest that certain step(s), such as virion assembly, intracellular trafficking, and secretion, are potentially up- and downregulated according to modifications of HCV envelope protein glycans. This Pol I-based HCV expression system will be beneficial for a high-throughput antiviral screening and vaccine discovery programs.


2013 ◽  
Vol 57 (5) ◽  
pp. 1694-1707 ◽  
Author(s):  
Sergey M. Dibrov ◽  
Jerod Parsons ◽  
Maia Carnevali ◽  
Shu Zhou ◽  
Kevin D. Rynearson ◽  
...  

2001 ◽  
Vol 276 (24) ◽  
pp. 20824-20826 ◽  
Author(s):  
Shuetsu Fukushi ◽  
Masato Okada ◽  
Joachim Stahl ◽  
Tsutomu Kageyama ◽  
Fuminori B. Hoshino ◽  
...  

2004 ◽  
Vol 11 (1) ◽  
pp. 72-94 ◽  
Author(s):  
Chih-Fei Kao ◽  
Shiow-Yi Chen ◽  
Yan-Hwa Wu Lee

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Philipp Schult ◽  
Hanna Roth ◽  
Rebecca L. Adams ◽  
Caroline Mas ◽  
Lionel Imbert ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document